Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06968312 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Hexadecanal as an Addon to Cognitive Processing Therapy for PTSD

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 16, 2025 (before its estimated September 30, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria shortened, about 3 wordsv2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Tel Aviv University
26 trials monitored
See 2 trials at risk
PTSD
889 trials monitored
See 54 trials at risk
This RCT investigates whether Cognitive Processing Therapy, a first line treatment for PTSD, can be enhanced by the use of the odor molecule Hexadecenal (HEX). HEX is secreted from body odor and has been shown to promotes psychological well-being and positive social interaction. For the active group Hex will be diffused in the treatment room during all treatment sessions. For the control group a vehicle placebo molecule will be diffused. Both therapists and patients will be blind to study condition.
Trial Details
NCT Number NCT06968312
Lead Sponsor Tel Aviv University
Collaborators: Weizmann Institute of Science
Conditions
(from sponsor)		 Post Traumatic Stress Disorder (PTSD)
Related terms Stress Disorders, Post-Traumatic
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov